KDC-MN-092 – Kodiac biolabs

Plain-language summaryIntrigue 70 / 100

Melanotan I (afamelanotide), sold as Scenesse, is a linear melanocortin receptor agonist approved for erythropoietic protoporphyria (a rare light-sensitivity disorder). It produces skin tanning by activating melanin synthesis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

49/100

FDA-approved EPP treatment with solid clinical evidence but a mature, well-characterized mechanism

Afamelanotide is one of the more unusual entries in any research library: it’s a drug with an approved indication, real phase 3 data, and a delivery mechanism (the subcutaneous implant) that you wont find anywhere else in peptide research. For erythropoietic protoporphyria the clinical case is settled. Patients tolerate meaningfully more light exposure without the painful phototoxic reactions that define the disease, and the effect size is clinically significant. That’s a real outcome, and we respect it.

The problem, from a research-merit standpoint, is that the mechanism is about as old as the peptide itself. The melanocortin system was being mapped in the 1980s when Mac Hadley’s group at Arizona synthesized this compound. MC1R drives melanin synthesis; MC4R handles appetite and sexual function; MC3R sits in between with roles in energy homeostasis and inflammation. Afamelanotide hits all four (MC1, MC3, MC4, MC5) non-selectively, with MC1 carrying most of the pharmacological weight in its approved indication. Thats not a novel mechanism. It’s well-characterized, multi-replicated, and the clinical approval closed most of the open questions about what the compound does in people.

We do think there’s a second story trying to emerge here. MC1R has anti-inflammatory signaling beyond its canonical pigmentation role, and some preclinical work has examined afamelanotide in contexts like solar UV-induced immunosuppression and cutaneous immune modulation. There’s a reasonable hypothesis that the photoprotective effect isn’t purely about melanin density but also involves MC1R-mediated modulation of Langerhans cell behavior and pro-inflammatory cytokine expression. Interesting. But multi-lab clinical evidence for those indications doesnt exist yet, and afamelanotide hasn’t broken out of the EPP box in terms of serious independent investigation.

On differentiation, afamelanotide occupies a clear position: it’s the approved linear analog, while Melanotan II (the cyclic analog) carries stronger MC4 agonism and all the associated appetite and sexual-function effects. If your research question is specifically MC1R-driven, afamelanotide is actually a cleaner probe than MT-II for reducing MC4 confounds. That’s worth something. The sustained-release implant formulation is also genuinely unique in peptide research and gives you pharmacokinetics that injection protocols simply cannot replicate for certain study designs.

The honest summary: afamelanotide has the best documentation of any melanocortin agonist in the library, but the questions it answers are mostly already answered. The live bench interest sits at the edges now, in the MC1R inflammation story and in EPP disease modeling. For investigators working specifically in those corners, it’s a solid tool. For general research programs, the novelty ceiling is real, and the score reflects that ceiling directly.

Novelty: 30
Mechanism promise: 38
In-category differentiation: 55
Evidence quality: 62
Translational signal: 70
Research bench value: 50

Rationale Scores as established-active: the EPP approval gives it real clinical evidence and a clear translational signal, but the melanocortin mechanism dates to the 1980s and most open questions are resolved. The only frontier angles are the MC1R anti-inflammatory story and EPP disease model work, which lift differentiation slightly but cannot rescue novelty above 30.

Alpha-MSH analog (linear heptadecapeptide)

A linear alpha-MSH analog approved as Scenesse for erythropoietic protoporphyria, characterized by sustained skin pigmentation.

Abstract

Melanotan I (Afamelanotide, Scenesse; (Nle4, D-Phe7)-alpha-MSH; CAS 75921-69-6; molecular formula C78H111N21O19; molecular weight 1646.85) is a linear heptadecapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH) developed at the University of Arizona by Mac Hadley’s group in the 1980s. The compound was approved by the FDA in 2019 (and earlier in Europe) for erythropoietic protoporphyria, a rare genetic photosensitivity disorder. Mechanism is non-selective melanocortin receptor agonism (MC1, MC3, MC4, MC5); the MC1 activity drives melanin synthesis in melanocytes producing tan-like skin pigmentation. The clinical formulation is a 16 mg subcutaneous implant providing sustained release over 60 days. The compound is sold as a research chemical/peptide for sunless tanning applications, though regulatory authorities have issued warnings against this use. Pharmacokinetics: subcutaneous administration; the implant formulation provides 30 to 60 days of activity per dose.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-092Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-092

Melanotan I (Afamelanotide)

Abstract

Read the full monograph